Analysts raise questions about AstraZeneca's interest in Gilead

Analysts raise questions about AstraZeneca's interest in Gilead

STAT Plus: Why would AstraZeneca want to buy Gilead? Some analysts say it’s not entirely clear

By ED SILVERMAN

RAPHAEL LAFARGUE/ABACA/SIPA USA VIA AP

The report that AstraZeneca might want to buy or merge with Gilead triggered speculation among Wall Street analysts about the merits of such a deal.

READ MORE